Inhibikase Therapeutics I... (IKT)
NASDAQ: IKT
· Real-Time Price · USD
1.74
0.03 (1.75%)
At close: Aug 15, 2025, 3:59 PM
1.75
0.47%
After-hours: Aug 15, 2025, 04:10 PM EDT
Inhibikase Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M | -4.48M | -4.28M | -4.49M | -4.64M | -4.64M | -5.04M | -4.47M | -2.64M | -2.64M |
Depreciation & Amortization | 12.65K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 6.58K | 159.2K | 5.04K | 5.04K | 1.68K | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 2.04M | 7.91M | 148.02K | 30.7K | 53.43K | 122.25K | 129.78K | 124.84K | 123.27K | 100.36K | 101.79K | 132.77K | 123.23K | 265.85K | 352.42K | 322.48K | 591.12K |
Other Working Capital | n/a | -70.67K | -1.04M | -528.47K | 243.35K | 680.23K | 27K | 1.15M | 216.73K | 197.88K | n/a | 97.12K | 799.76K | 224.28K | 2.25M | -2.34M | -1.15M |
Other Non-Cash Items | n/a | -1.13M | 1.33M | 30.7K | -412.7K | 237.44K | 17.28K | 663.27K | 350.09K | -20.82K | 20.82K | 37.09K | 67K | 29.84K | 181.76K | 239.41K | 270.61K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -223.18K | n/a | -663.27K | -350.09K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | -1.13M | -590.58K | -132.03K | 722.62K | 592.44K | 336.46K | 928.53K | -1.62M | 638.09K | -1.13M | 151.37K | 516.17K | 650.11K | 1.92M | -2.17M | -2.16M |
Operating Cash Flow | -4.1M | -5.35M | -4.88M | -5.05M | -3.87M | -3.44M | -4.11M | -4.57M | -5.97M | -3.56M | -5.5M | -4.36M | -3.93M | -4.1M | -2.02M | -4.25M | -3.93M |
Capital Expenditures | n/a | n/a | -4 | 4.00 | n/a | 14.24K | n/a | -14.24K | n/a | 200.17K | -200.17K | -43.09K | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -14.24K | n/a | 14.24K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | -50.11M | -1.13M | -776.97K | -8.43M | -8.8M | -1.95M | 2.93M | -21.61M | -15.76M | -20.73M | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 21.51M | 11.35M | 3.66M | 3.32M | 5.12M | 6.68M | 19.01M | -365.65K | 15.77M | 4.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -452.02K | n/a | n/a | n/a | -3.31M | -2.12M | 17.06M | -14.24K | -5.84M | 15.56M | -20.73M | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 21.05M | -38.76M | 2.53M | 2.54M | -3.31M | -2.12M | 17.06M | 2.55M | -5.84M | 4.96M | -20.93M | -43.09K | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -248.91K | n/a | n/a | 367.13K | -409.66K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | 30.61K | -30.61K | -138.56K | n/a | n/a | n/a | n/a | n/a | -248.91K | 44.14K | 41.01M | 29.89K | -43.3K | n/a |
Financial Cash Flow | n/a | 99.68M | 181.95K | 3.24M | 367K | -138.1K | 70.00 | -35.99K | 8.58M | -204.77K | n/a | -248.91K | -204.77K | n/a | 29.89K | 41.47M | -409.66K |
Net Cash Flow | 16.95M | 55.58M | -2.17M | 733.11K | -6.81M | -5.7M | 12.96M | -2.05M | -3.23M | 1.41M | -26.43M | -4.4M | -4.14M | -4.1M | -1.99M | 37.23M | -4.34M |
Free Cash Flow | -4.1M | -5.35M | -4.88M | -5.05M | -3.87M | -3.43M | -4.11M | -4.58M | -5.97M | -3.36M | -5.7M | -4.4M | -3.93M | -4.1M | -2.02M | -4.25M | -3.93M |